Advances in Prostate Cancer: Androgen Deprivation Therapy Across the Disease Continuum

Join us online for an interactive symposium at AUA 2021 in Las Vegas, Nevada, featuring current clinical guidance and perspectives from recognized experts on the optimal use of androgen deprivation therapy for nonmetastatic or metastatic prostate cancer. Sign up now!

Agenda

Defining Castration Sensitivity in Metastatic and Nonmetastatic Prostate Cancer

Advances in Nonmetastatic Castration-Resistant Prostate Cancer

Advances in Metastatic Hormone-Sensitive Prostate Cancer/Metastatic Castration-Naive Prostate Cancer

Practical Clinical Applications for AR Inhibitor Therapy

Program will include patient case examples and clinical scenarios and time for you to ask questions and hear answers from the experts.

Events

Date / Time
Event Details

Faculty

Faculty
Daniel W. Lin, MD

Professor and Chief of Urologic Oncology
Department of Urology
University of Washington
Seattle, Washington

Faculty
Alicia K. Morgans, MD

Faculty
David F. Penson, MD

Professor and Chair
Department of Urology
Vanderbilt University School of Medicine
Nashville, Tennessee

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with prostate cancer.

Target Audience
This program is intended for urologists and other healthcare professionals who care for patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients who are likely to benefit from newly available therapeutic options for nonmetastatic prostate cancer
  • Plan optimal, individualized therapeutic strategies for nonmetastatic or metastatic castration-sensitive prostate cancer
  • Apply guidelines and expert recommendations for the sequencing of available and emerging therapies (alone and in combination) for patients with prostate cancer
  • Assess and manage the risk for cardiotoxicity or bone loss before and/or during prostate cancer treatment
  • Counsel patients about available ADTs, taking into consideration patient preferences and comorbidities with regard to differences in administration and safety profiles
  • Refer appropriate patients with prostate cancer to ongoing clinical trials assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.